HRP20020934B1 - 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis - Google Patents

5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis

Info

Publication number
HRP20020934B1
HRP20020934B1 HR20020934A HRP20020934A HRP20020934B1 HR P20020934 B1 HRP20020934 B1 HR P20020934B1 HR 20020934 A HR20020934 A HR 20020934A HR P20020934 A HRP20020934 A HR P20020934A HR P20020934 B1 HRP20020934 B1 HR P20020934B1
Authority
HR
Croatia
Prior art keywords
methanesulfonylphenyl
bipyridinyl
chloro
synthesis
methyl
Prior art date
Application number
HR20020934A
Other languages
English (en)
Croatian (hr)
Inventor
S. Crocker Louis
Ian Davies W.
G. Osifchin Richard
Kotliar Andrew
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22772880&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020934(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20020934A2 publication Critical patent/HRP20020934A2/hr
Publication of HRP20020934B1 publication Critical patent/HRP20020934B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR20020934A 2000-05-26 2002-11-25 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis HRP20020934B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20801700P 2000-05-26 2000-05-26
PCT/US2001/016566 WO2001092230A1 (en) 2000-05-26 2001-05-22 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis

Publications (2)

Publication Number Publication Date
HRP20020934A2 HRP20020934A2 (en) 2005-02-28
HRP20020934B1 true HRP20020934B1 (en) 2012-01-31

Family

ID=22772880

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020934A HRP20020934B1 (en) 2000-05-26 2002-11-25 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis

Country Status (49)

Country Link
EP (1) EP1296951B1 (uk)
JP (2) JP3665053B2 (uk)
KR (1) KR100757699B1 (uk)
CN (1) CN1227233C (uk)
AR (1) AR028577A1 (uk)
AT (1) ATE483687T1 (uk)
AU (2) AU6480401A (uk)
BG (1) BG65855B1 (uk)
BR (1) BRPI0111140B8 (uk)
CA (1) CA2410234C (uk)
CR (1) CR6606A (uk)
CY (1) CY1111440T1 (uk)
CZ (1) CZ20023888A3 (uk)
DE (1) DE60143197D1 (uk)
DK (1) DK1296951T3 (uk)
EA (1) EA004809B1 (uk)
EE (1) EE05242B1 (uk)
EG (1) EG24189A (uk)
ES (1) ES2351958T3 (uk)
GC (1) GC0000362A (uk)
GE (1) GEP20053492B (uk)
GT (1) GT200100091A (uk)
HK (1) HK1058932A1 (uk)
HN (1) HN2001000110A (uk)
HR (1) HRP20020934B1 (uk)
HU (1) HU228423B1 (uk)
IL (1) IL152582A0 (uk)
IN (2) IN2002CH02089A (uk)
IS (1) IS2806B (uk)
JO (1) JO2216B1 (uk)
MA (1) MA26919A1 (uk)
ME (1) ME00428B (uk)
MX (1) MX230696B (uk)
MY (1) MY123569A (uk)
NO (1) NO324495B1 (uk)
NZ (1) NZ522394A (uk)
PA (1) PA8516901A1 (uk)
PE (1) PE20011324A1 (uk)
PH (1) PH12001001175B1 (uk)
PL (1) PL358153A1 (uk)
PT (1) PT1296951E (uk)
RS (1) RS51541B (uk)
SI (1) SI1296951T1 (uk)
SK (1) SK287174B6 (uk)
SV (1) SV2002000462A (uk)
TW (1) TWI303634B (uk)
UA (1) UA73355C2 (uk)
WO (1) WO2001092230A1 (uk)
ZA (1) ZA200209558B (uk)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1248618T3 (da) * 1999-11-29 2006-07-10 Merck Frosst Canada Inc Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
EP2479166B1 (en) 2009-02-27 2014-08-20 Cadila Healthcare Limited A process for the preparation of etoricoxib
WO2012004677A1 (en) 2010-07-05 2012-01-12 Actavis Group Ptc Ehf Solid state forms of etoricoxib salts
SI2714676T1 (sl) 2011-05-27 2019-06-28 Farma Grs, D.O.O. Postopek za pripravo polimorfne oblike I etorikoksiba
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
EP2888231B1 (en) * 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Process for preparation of crystalline etoricoxib
EP2887924B1 (en) 2012-08-27 2017-03-29 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN106632003B (zh) * 2015-12-31 2019-02-12 上海博志研新药物技术有限公司 一种依托考昔的制备方法
CN108069896B (zh) * 2016-11-11 2022-08-12 昆明积大制药股份有限公司 一种依托考昔晶型的制备方法
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
CN107417599B (zh) * 2017-06-21 2020-06-09 四川尚锐生物医药有限公司 一种依托考昔晶型的制备方法
MX2017009660A (es) 2017-07-26 2017-11-23 Laboratorios Liomont S A De C V Composicion farmaceutica con un rango de relacion entre el clorhidrato de tramadol y el etoricoxib para su administracion para el tratamiento del dolor.
CN107556231A (zh) * 2017-09-23 2018-01-09 江苏正大清江制药有限公司 一种依托考昔与对硝基苯甲酸形成的盐的晶型及制备方法
CN107417600A (zh) * 2017-09-26 2017-12-01 江苏正大清江制药有限公司 一种依托考昔与呋喃甲酸形成盐的新晶型及制备方法
CN107898787B (zh) * 2017-12-15 2018-11-30 扬子江药业集团上海海尼药业有限公司 一种药物组合物及其制剂和制备方法
WO2019130049A1 (en) 2017-12-29 2019-07-04 Grünenthal GmbH Pharmaceutical combination comprising extended-release tramadol hydrochloride and immediate-release etoricoxib, and its use for the treatment of pain
CN110143915A (zh) * 2019-06-03 2019-08-20 蚌埠学院 一种依托考昔与对甲苯磺酸形成盐的新晶型及制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003484A1 (en) * 1996-07-18 1998-01-29 Merck Frosst Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO1999055830A2 (en) * 1998-04-24 1999-11-04 Merck & Co., Inc. Process for synthesizing cox-2 inhibitors
WO2001037833A1 (en) * 1999-11-29 2001-05-31 Merck Frosst Canada & Co. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998003484A1 (en) * 1996-07-18 1998-01-29 Merck Frosst Canada Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
WO1999055830A2 (en) * 1998-04-24 1999-11-04 Merck & Co., Inc. Process for synthesizing cox-2 inhibitors
WO2001037833A1 (en) * 1999-11-29 2001-05-31 Merck Frosst Canada & Co. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Also Published As

Publication number Publication date
YU89402A (sh) 2005-11-28
IN2002CH02089A (uk) 2005-02-25
HUP0302336A2 (hu) 2003-11-28
NO20025674L (no) 2002-11-26
ES2351958T3 (es) 2011-02-14
IL152582A0 (en) 2003-05-29
TWI303634B (en) 2008-12-01
BR0111140A (pt) 2005-01-11
MX230696B (es) 2005-09-19
SI1296951T1 (sl) 2011-01-31
GT200100091A (es) 2001-12-28
HU228423B1 (en) 2013-03-28
CY1111440T1 (el) 2015-08-05
JO2216B1 (en) 2004-10-07
CN1227233C (zh) 2005-11-16
EP1296951A1 (en) 2003-04-02
MY123569A (en) 2006-05-31
PH12001001175B1 (en) 2006-08-10
JP3665053B2 (ja) 2005-06-29
RS51541B (sr) 2011-06-30
HRP20020934A2 (en) 2005-02-28
HN2001000110A (es) 2002-03-06
AU6480401A (en) 2001-12-11
BG65855B1 (bg) 2010-03-31
CA2410234C (en) 2008-05-13
CA2410234A1 (en) 2001-12-06
BG107237A (bg) 2003-05-30
CR6606A (es) 2006-02-06
BRPI0111140B1 (pt) 2018-03-13
AU2001264804B2 (en) 2006-04-06
ATE483687T1 (de) 2010-10-15
ZA200209558B (en) 2003-10-28
SK16702002A3 (sk) 2003-05-02
CN1443168A (zh) 2003-09-17
IN2007CH05103A (uk) 2008-08-27
GC0000362A (en) 2007-03-31
EE200200655A (et) 2004-08-16
PE20011324A1 (es) 2002-01-28
DE60143197D1 (de) 2010-11-18
PA8516901A1 (es) 2002-04-25
IS6630A (is) 2002-11-20
SK287174B6 (sk) 2010-02-08
EA004809B1 (ru) 2004-08-26
ME00428B (me) 2011-10-10
JP4142621B2 (ja) 2008-09-03
NO20025674D0 (no) 2002-11-26
MA26919A1 (fr) 2004-12-20
NO324495B1 (no) 2007-10-29
WO2001092230A1 (en) 2001-12-06
CZ20023888A3 (cs) 2003-02-12
GEP20053492B (en) 2005-04-25
EP1296951B1 (en) 2010-10-06
DK1296951T3 (da) 2011-01-24
EA200201264A1 (ru) 2003-04-24
IS2806B (is) 2012-09-15
PL358153A1 (en) 2004-08-09
EG24189A (en) 2008-10-08
AR028577A1 (es) 2003-05-14
HK1058932A1 (en) 2004-06-11
MXPA02011619A (es) 2003-03-27
SV2002000462A (es) 2002-03-08
JP2005047927A (ja) 2005-02-24
KR100757699B1 (ko) 2007-09-13
PT1296951E (pt) 2010-12-07
UA73355C2 (en) 2005-07-15
NZ522394A (en) 2004-05-28
EE05242B1 (et) 2009-12-15
JP2004501116A (ja) 2004-01-15
KR20030003762A (ko) 2003-01-10
BRPI0111140B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
HRP20020934B1 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis
HRP20060361A8 (en) Novel c-crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same
AP1452A (en) Novel y crystalline form of perindopril tert-butylamine salt preparation method, and pharmaceutical compositions containing same.
HRP20000168B1 (en) Resorcinol derivatives
RS49870B (sr) Polimorfni oblik klopidogrel vodonik sulfata
CA2508824A1 (fr) Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
RS51210B (sr) Dobijanje pregaballina i srodnih jedinjenja
IL181298A0 (en) Solid and crystalline ibandronate sodium and processes for preparation thereof
CA2415438A1 (fr) Forme cristalline .alpha. du sel de tert-butylamine du perindopril
GB0112348D0 (en) Compounds
BR0108947A (pt) Método para preparação e citalopram; intermediário e sua composição farmacêutica
JO2493B1 (en) New phenyl azatidinone with improved physical properties and methods of preparation of drugs containing it and its uses
HRP20000171B1 (en) Oral compositions of levosimendan
BR0206372A (pt) Processo para sintetizar um composto
MXPA02009643A (es) Sintesis acortada de derivados de 3,3-diarilpropilamina.
MEP15708A (en) Lithium complexes of n-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane, production and use thereof
UA72945C2 (uk) Сполука (варіанти), фармацевтична композиція, спосіб лікування (варіанти)
WO2001023377A3 (en) Polymorphic salt
GB0212410D0 (en) Organic compounds
DE60206068D1 (de) Aralkyltetrahydropyridine, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
TW200502235A (en) Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof
KR870007930A (ko) 5-치환된 옥타하이드로 인돌리진 및 그의 제조 방법
WO2001080906A3 (en) Radiometal complexes of 2-pyrrolylthiones for imaging a therapy
AU5125798A (en) Novel n-benzenesulphonyl-l-proline derivatives, method for preparing and therapeutic use
ATE355281T1 (de) 1,4,7,10-tetraazacyclododecan-1,4-diessigsäure

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: SCHERING CORPORATION, US

Owner name: MERCK SHARP & DOHME CORP., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190507

Year of fee payment: 19

ODRP Renewal fee for the maintenance of a patent

Payment date: 20200505

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20210522